Neuroscience-focused digital data analysis technology developer IXICO has signed two new biopharmaceutical client contracts worth a total of more than £1m.
An ongoing phase III study has been extended and this will add £900,000 to the contract value.
One study has been discontinued following an interim review of data. It will not affect revenue this year, but contracted revenues of £3.5m were expected up until 2025.
© 2020 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Aeorema Communications is being hit be the postponement of events.
Walcom Group is short of cash and the chief executive has been unable to provide the funds he intended to lend to the company.
Broadcast software provider Pebble Beach Systems has delayed its 2019 figures due to COVID-19.